Granules seeks first-to-file status for generic cancer drug Ruxolitinib
In short
Granules said it is trying to get first-to-file status and 180 days of exclusivity for a generic version of the cancer drug Ruxolitinib in the U.S. It also said it sent the required notice under U.S. rules.
This could matter for sales if the company wins the exclusivity, but the reporting does not say whether there is a court fight or when approval might come. The exact outcome is still unknown.
What the reporting says
Granules said it is seeking first-to-file status and 180 days of exclusivity for a generic version of cancer drug Ruxolitinib in the U.S., according to a publisher-supplied summary. The reported Paragraph IV certification relates to patents listed in the U.S. FDA Orange Book, and the company said it issued the required notice to relevant parties. The available reporting does not say whether litigation has started or when approval could follow.
Why it matters
Granules said it is pursuing first-to-file status and 180 days of exclusivity for a generic Ruxolitinib in the U.S., with a Paragraph IV certification tied to patents listed in the FDA’s Orange Book. The company said it has sent the required notice to relevant parties. The reporting does not state the legal status beyond that or whether the filing will lead to approval or litigation.